Triple Receptor Agonist

TRIUMPH-1 Trial: Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with Obesity

by Prateek Chopra | June 29, 2026 | Diabetes Conferences | ADA 2026 Therapeutic Overview TRIUMPH-1 Trial Design Weight Loss Outcomes Impact on Obesity Status Cardiometabolic Benefits Effects on Obesity-Related Conditions Clinical Implications In the phase 3 TRIUMPH-1 trial, retatrutide produced marked and sustained weight loss, with many participants no longer meeting criteria for obesity after treatment. The associated improvements […]

TRIUMPH-1 Trial: Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with Obesity Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

TRANSCEND-T2D-1: Results of First Phase 3 Study of Retatrutide, a GIP,GLP-1, and Glucagon Receptor Agonist in Patientswith T2D

by Prateek Chopra | June 29, 2026 | Diabetes Conferences | ADA 2026 Trial Overview Study Design Glycemic Outcomes Weight Loss Outcomes Cardiometabolic Benefits Safety Outcomes Clinical Implications In the TRANSCEND-T2D-1 trial, retatrutide produced substantial reductions in HbA1c and body weight, along with improvements in cardiovascular risk factors. These findings support its potential as an effective treatment option for managing

TRANSCEND-T2D-1: Results of First Phase 3 Study of Retatrutide, a GIP,GLP-1, and Glucagon Receptor Agonist in Patientswith T2D Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,
Scroll to Top